Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

12.82 -0.66 (-4.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Novocure (NASDAQ:NVCR) Q3 2025 Earnings: Revenue Beat and Narrower Loss Drive Shares Higher
Novocure (NVCR) beat Q3 2025 revenue estimates and narrowed its loss, with shares rising. The oncology firm is expanding its Tumor Treating Fields therapy into new cancers. 
Via Chartmill
Earnings Scheduled For October 30, 2025
 
Via Benzinga
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts
Investment bank analysts up and down Wall Street are pounding the table on these stocks. 
Via The Motley Fool
Top 3 Health Care Stocks That May Explode In July
 
Via Benzinga
NovoCure Q2 Revenue Jumps 6 Percent
Via The Motley Fool
Topics World Trade
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Earnings Scheduled For July 24, 2025
 
Via Benzinga
NovoCure Earnings Preview
 
Via Benzinga
Earnings Scheduled For April 24, 2025
 
Via Benzinga
Novocure: Steady Ahead of Key Milestones
Via The Motley Fool
This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Demystifying NovoCure: Insights From 4 Analyst Reviews
 
Via Benzinga
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
 
Via Benzinga
NovoCure's Earnings: A Preview
 
Via Benzinga
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why
Via The Motley Fool
Earnings Scheduled For February 27, 2025
 
Via Benzinga
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings)
 
Via Benzinga
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
TTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data from the PANOVA-3 trial. 
Via Benzinga
1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street
Via The Motley Fool
Why NovoCure Stock Skyrocketed This Week
Via The Motley Fool
Topics Earnings Stocks
Why NovoCure Stock Leaped 4% Higher Today
Via The Motley Fool
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
NovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs. 
Via Benzinga
Topics World Trade
NovoCure Surpasses Q1 Expectations
NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why NovoCure Stock Was Withering on Wednesday
Via The Motley Fool
NovoCure (NVCR) Q4 2024 Earnings Call Transcript
NVCR earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025
NovoCure's Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio's expansion. 
Via Benzinga
NovoCure Q4 EPS Misses, Revenue Matches
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges. 
Via The Motley Fool
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business." 
Via Benzinga
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?
These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.